COCH Nasdaq Orthopedic, Prosthetic & Surgical Appliances & Supplies Financials FY2021βFY2025
Envoy Medical, Inc. had $0.2M of revenue in fiscal 2025, up 7.1% on the year before.
Last close Β· Oct 23, 2026
$0.60
0.1%Hi! I read Envoy Medical, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+7.1%
Yes. Sales grew 7.1% last year.
Does it make a profit?
β9,857.3%
No. It lost money last year.
Does profit turn into cash?
β7,626.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Envoy Medical, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 9, 2026
Monday Β· in 14 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 10, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 11, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Mar 23, 2026 | Q4 '25 | Time not announced | 8-K β |
| Nov 10, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Jul 31, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 1, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 31, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 14, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Envoy Medical, Inc. had $0.2M of revenue in fiscal 2025, up 7.1% on the year before. Its operating margin was β9,240.7%, down 682.4Β pts: of every 100 in sales, about β9,241 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Envoy Medical, Inc. lost $23.8M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$18.4M in fiscal 2025, β7,626.6% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Envoy Medical, Inc. returned $1.8M to shareholders in fiscal 2025. The diluted share count rose 23.8%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Envoy Medical, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $0.1M | $0.2M | $4.2M | $5.5M | $3.7M |
| Interest coverage | β | β | β | β23.6x | β14.0x |
| Current ratio | 0.3x | 0.7x | 1.0x | 1.2x | 0.5x |
| Quick ratio | 0.3x | 0.1x | 0.8x | 1.0x | 0.4x |
| Total assets | $427M | $2.6M | $8.3M | $11.5M | $8.6M |
| Total liabilities | $38.6M | $38.8M | $10.0M | $30.4M | $20.3M |
| Shareholders' equity | β$45.0M | β$36.2M | β$1.8M | β$18.8M | β$12.2M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Envoy Medical, Inc. passes 2 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β |
| F-score | β / 3 | β / 5 | 3 / 8 | 3 / 8 | 2 / 8 |
| Accruals ratio | 0.7% | β3.3% | β237.0% | β28.7% | β55.3% |
| Altman Z'' | β1.61 | β314.33 | β116.36 | β91.54 | β141.55 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | β | $0.2M | $0.3M | $0.2M | $0.2M |
| Gross profit | β | β$0.3M | β$0.5M | β$0.5M | β$0.6M |
| Research and development | β | $5.0M | $9.0M | $10.2M | $12.5M |
| Operating income | β$5.2M | β$8.7M | β$18.4M | β$19.3M | β$22.3M |
| Interest expense | β | β | β | $0.8M | $1.6M |
| Pretax income | β$0.3M | $20.7M | β | β$20.8M | β$23.8M |
| Income tax | β | $1.5M | β | β | β |
| Net income | β$0.3M | β$15.9M | β$29.9M | β$20.8M | β$23.8M |
| Net income to common | β | β$15.9M | β$31.3M | β$28.0M | β$28.7M |
| Diluted EPS | β | β$1.57 | β$2.54 | β$1.49 | β$1.23 |
| Diluted shares | β | 0.01B | 0.01B | 0.02B | 0.02B |
| Cash flow | |||||
| Cash from operations | β$3.2M | β$8.8M | β$17.1M | β$17.9M | β$18.2M |
| Capital expenditure | β | $0.2M | $0.2M | $1.0M | $0.2M |
| Free cash flow | β | β$9.0M | β$17.2M | β$18.9M | β$18.4M |
| Depreciation and amortization | β | $0.1M | $0.1M | $0.2M | $0.3M |
| Stock-based compensation | β | $0.0M | $1.6M | $0.6M | $0.7M |
| Dividends paid | β | β | β | $2.4M | $1.8M |
| Dividends and buybacks | β | β | β | $2.4M | $1.8M |
| Balance sheet | |||||
| Cash and short-term investments | $0.1M | $0.2M | $4.2M | $5.5M | $3.7M |
| Current assets | $0.9M | $1.6M | $7.5M | $8.9M | $6.3M |
| Current liabilities | $2.7M | $2.5M | $7.3M | $7.5M | $11.6M |
| Inventory | β | $1.3M | $1.4M | $1.7M | $1.5M |
| Property and equipment, net | β | $0.3M | $0.4M | $1.3M | $1.0M |
| Total assets | $427M | $2.6M | $8.3M | $11.5M | $8.6M |
| Total liabilities | $38.6M | $38.8M | $10.0M | $30.4M | $20.3M |
| Shareholders' equity | β$45.0M | β$36.2M | β$1.8M | β$18.8M | β$12.2M |
| Margins | |||||
| Gross margin | β | β110.1% | β149.7% | β229.8% | β262.7% |
| Operating margin | β | β3,673.4% | β5,809.8% | β8,558.2% | β9,240.7% |
| EBITDA margin | β | β3,641.8% | β5,767.7% | β8,481.3% | β9,115.4% |
| Net margin | β | β6,718.6% | β9,469.0% | β9,242.2% | β9,857.3% |
| FCF margin | β | β3,807.2% | β5,457.0% | β8,412.9% | β7,626.6% |
| Returns | |||||
| Return on capital employed | β1.2% | β23,529.7% | β1,862.0% | β481.4% | 741.3% |
| Return on assets | β0.1% | β7.4% | β552.7% | β210.0% | β236.4% |
| Growth | |||||
| Revenue growth | β | β | 33.3% | β28.8% | 7.1% |
| Share count change | β | β | 21.5% | 52.8% | 23.8% |
| Financial health | |||||
| Interest coverage | β | β | β | β23.6x | β14.0x |
| Current ratio | 0.3x | 0.7x | 1.0x | 1.2x | 0.5x |
| Quick ratio | 0.3x | 0.1x | 0.8x | 1.0x | 0.4x |
| Capital allocation | |||||
| Capex / revenue | β | 92.0% | 48.4% | 435.6% | 74.3% |
| Stock comp / revenue | β | 0.0% | 498.4% | 249.8% | 272.6% |
| Quality scores | |||||
| Piotroski F-score | β | β | 3.0 | 3.0 | 2.0 |
| Altman Z'' | β1.6 | β314.3 | β116.4 | β91.5 | β141.5 |
| Accruals ratio | 0.7% | β3.3% | β237.0% | β28.7% | β55.3% |
Source: SEC EDGAR XBRL filings (CIK 0001840877). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
